The Effect of Administering Erythropoiesis‐Stimulating Proteins in Patients With Chronic Heart Failure: Results From a Retrospective Study

Anemia is prevalent in patients with chronic heart failure and is associated with worse symptoms and poor prognosis. The authors reviewed the charts of all patients (N=467) treated at Texas Heart Institute from January 2000 to October 2003, during which time a clinical protocol offered treatment wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Congestive heart failure (Greenwich, Conn.) Conn.), 2006-11, Vol.12 (6), p.297-301
Hauptverfasser:	Delgado, Reynolds M., Radovancevic, Rajko, Rossem, Charles C., Gaemers, Sebastiaan J.M., Castanes, Stratego, Adams, Stephen C., Bracey, Arthur W., Radovancevic, Branislav
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anemia - blood Anemia - drug therapy Anemia - etiology Erythropoietin - therapeutic use Female Heart Failure - blood Heart Failure - complications Heart Failure - drug therapy Hematinics Hemoglobins - analysis Hospitalization - statistics & numerical data Humans Male Middle Aged Natriuretic Peptide, Brain - blood Recombinant Proteins Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Anemia is prevalent in patients with chronic heart failure and is associated with worse symptoms and poor prognosis. The authors reviewed the charts of all patients (N=467) treated at Texas Heart Institute from January 2000 to October 2003, during which time a clinical protocol offered treatment with erythropoiesis‐stimulating proteins. Post‐treatment, the authors observed a significant increase in mean ± SD hemoglobin, from 9.9±1.1 g/dL to 11.7±1.5 g/dL (P
ISSN:	1527-5299 1751-7133
DOI:	10.1111/j.1527-5299.2006.05704.x